Seattle Genetics (SGEN). Atentos a este valor.
Ambos han trabajado juntos antes, estudiando combinaciones de medicamentos contra el cáncer de Seattle Genetics con el medicamento de gran éxito de Merck, Keytruda. Ahora Merck adquirirá una participación de US$1.000 millones en la empresa de biotecnología. Una inversión de 5 millones de acciones que se comprarán a US$200 cada una, que representa una prima de 33% frente al cierre del viernes, colocará a Merck entre los diez principales accionistas de Seattle Genetics, con sede en Bothell, Washington.
| By Simon Barnett | @sbarnettARK
| Surprisingly, after 17 years the whole human genome has not been sequenced completely. Since they sequenced the first whole human genome in 2003, scientists have struggled to identify small gaps scattered among the 23 pairs of chromosomes.
These dark genes have limited our understanding of genetics, evolution, and human disease. Dark genes contain long, highly repetitive stretches of DNA that short-read sequencers cannot interpret. Many errors take place during sample preparation, making it difficult or impossible to overcome with software tools. Last week, researchers published a complete sequence of chromosome eight (8)—the first non-sex chromosome to be sequenced completely.
The team identified the 2.3% of chromosome 8’s missing - or dark - genes with a combination of long-read instruments from Oxford Nanopore Technologies (ONT) and Pacific Biosciences (PACB). Unlike short-read platforms, the more expensive long-read platforms can sequence ‘hard-to-read’ areas of the genome. Among other discoveries, the researchers found a 644,000-base pair (bp) region in a gene cluster - DEFB1 -seemingly implicated in cystic fibrosis (CF). Apparently, DEFB1 encodes proteins that equip the immune system to fight off bacterial infections in airways, suggesting that mutations in DEFB1 could influence the severity of CF. While geneticists typically have diagnosed CF by identifying mutations in the CFTR gene, other genetic factors such as mutations in DEFB1 will help them diagnose the course of the disease more accurately. In our view, diagnostic testing companies must invest aggressively in long read sequencers and other tools, or they will fall victim to disruptive innovation.